Ligands of CD6: roles in the pathogenesis and treatment of cancer by Mikel Gurrea-Rubio, Feng Lin, Max S. Wicha, Yang Mao-Draayer, David A. Fox

“…Therefore, there has been an increased focus on understanding how CD6 interacts with its ligands in the context of cancer biology and cancer immunotherapy. In this review, we assess the roles of these CD6 ligands in both the pathogenesis and treatment of cancer.…”
Get full text

Neoantigen mRNA vaccines and A2A receptor antagonism: A strategy to enhance T cell immunity by Saber Imani, Parham Jabbarzadeh Kaboli, Ali Babaeizad, Mazaher Maghsoudloo

“…This synergy represents significant progress in cancer immunotherapy, advancing the potential for personalized neoantigen therapies.…”
Get full text

Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge by Bairu Shen, Zi Guo, Peng Huang, Minghua Tan, Xiaoshen Zhang, Siyao Lin, Changshan Song, Jiaqing Wang, Minqian Huang

“…We collected retrospective studies on “post-transplantation, cancer, immunotherapy, and vascular targeting therapy” in Embase, Wanfang database, Cochrane Library, VIP databases, CNKI, and PubMed, and the case data were organized and analyzed. …”
Get full text

Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer by Beatriz Ramos, Dakota Rogers

“…Additionally, nanovaccine strategies incorporating tumor-associated antigens and immune adjuvants show potential for personalized cancer immunotherapy. Here, we discuss the immune landscape of bladder cancer, explore the emerging immunotherapies being used as bladder cancer treatment, and discuss the advantages of using nanoparticles as carriers of immunotherapies against bladder cancer. …”
Get full text

Comparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis by Zihao Chen, Xin Chen, Dingchao Li, Jingang jian, Chang Yao, Xuedong Wei, Jianquan Hou

Get full text

Cancer vaccines: platforms and current progress by Wanting Lei, Kexun Zhou, Ye Lei, Qiu Li, Hong Zhu

“…By addressing these challenges, cancer vaccines can offer significant improvements in patient outcomes and broaden the scope of personalized cancer immunotherapy.…”
Get full text

MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers by Ibrahim Halil Erdogdu

“…Despite the use of VEGF-, EGFR-, and HER2-targeting agents, prognosis is still poor in advanced gastric cancer. Although cancer immunotherapy responds well in some patients, clinical use is limited due to unanswered patients. …”
Get full text

Oncolytic reprogramming of tumor microenvironment shapes CD4 T-cell memory via the IL6ra-Bcl6 axis for targeted control of glioblastoma by Jeffrey M. Grimes, Sadashib Ghosh, Shamza Manzoor, Li X. Li, Monica M. Moran, Jennifer C. Clements, Sherrie D. Alexander, James M. Markert, Jianmei W. Leavenworth

“…Abstract Oncolytic viruses (OVs) emerge as a promising cancer immunotherapy. However, the temporal impact on tumor cells and the tumor microenvironment, and the nature of anti-tumor immunity post-therapy remain largely unclear. …”
Get full text

TGF‐β regulates the release of breast cancer cell‐derived extracellular vesicles and the sorting of their protein cargo by downregulating RAB27B expression by Chao Li, Agustin Enciso‐Martinez, Roman I. Koning, Mona Shahsavari, Peter ten Dijke

“…Our findings reveal the critical roles of TGF‐β and RAB27B in cancer development by regulating EV release and composition and thus provide potential targets to improve cancer immunotherapy.…”
Get full text

Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy by Jie Ma, Hongtao Wang, Zhengwei Gui, Yuanrong Yang

“…SYNGR4 overexpression affects breast cancer proliferation, migration, and tumor immune infiltration, and promotes breast cancer tumor-associated macrophage polarization toward M2.DiscussionSYNGR4 overexpression can affect the prognosis of breast cancer patients by promoting M2 polarization of tumor-associated macrophages in breast cancer, and this molecule may be a novel target for breast cancer immunotherapy.…”
Get full text

The first case of esophageal mediastinal fistula after immunotherapy for non-small cell lung cancer: case report and literature review by Tianxiao Fu, Jiu Chen, Bing Xiong, Guolin Wu

Get full text

Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions by Lisheng Ge, Neil Hoa, Daniela A. Bota, Josephine Natividad, Andrew Howat, Martin R. Jadus

“…Immunotherapy offers the opportunity to allow the patient's own immune system a chance to help eliminate the cancer. Immunotherapy's strength is that it efficiently treats relatively small tumors in experimental animal models. …”
Get full text

Investigation of CD47 Expression in Renal Cell Tumors and Evaluation of Its Relationship with Prognostic Parameters by Ömer Faruk Dizibüyük, Zehra Bozdağ, Metin Karakök

“…Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (STs) and hematological malignancies. …”
Get full text

Cancer theragnostics: closing the loop for advanced personalized cancer treatment through the platform integration of therapeutics and diagnostics by Olga V. Sergeeva, Liang Luo, Anthony Guiseppi-Elie, Anthony Guiseppi-Elie, Anthony Guiseppi-Elie

“…However, a major challenge in cancer immunotherapy is to predict which patients will respond to treatment and to monitor the efficacy of the vaccine during treatment. …”
Get full text

Dual Roles of IL-27 in Cancer Biology and Immunotherapy by Marina Fabbi, Grazia Carbotti, Silvano Ferrini

“…Here, we will summarize IL-27 biological activities and its functional overlaps with the IFNs and discuss its dual role in tumors in the light of potential applications to cancer immunotherapy.…”
Get full text

Tumor microenvironment–responsive and modulatory manganese-based nanoenzyme for enhanced tumor immunotherapy by Qi Yang, Qiong Wu, Haiyan Liu, Jiandong Wu, Feng Ma, Xiaofeng Tian

“…The characteristics of the tumor microenvironment (TME) have a close and internal correlation with the effect of cancer immunotherapy, significantly affecting the progression and metastasis of cancer. …”
Get full text

Q11, a CYP2E1 inhibitor, exerts anti-hepatocellular carcinoma effect by inhibiting M2 macrophage polarization by Cunzhen Zhang, Yan Fang, Mengxue Guo, Liming Tang, Yurong Xing, Jun Zhou, Yuanyuan Guo, Yuhan Gu, Qiang Wen, Na Gao, Haiwei Xu, Hailing Qiao

“…Abstract Despite significant advancements in cancer immunotherapy, many patients continue to respond poorly. …”
Get full text

Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes by Yan-Hua Wang, Shotaro Hagiwara, Hiroshi Kazama, Yuki Iizuka, Norina Tanaka, Junji Tanaka

“…Combination therapy using antibodies and natural killer (NK) effectors, which are innate immune cells with safe and potent antitumor activity, is a promising approach for cancer immunotherapy and can enhance antitumor effects. Elotuzumab (Elo) is an immune-stimulatory antibody that targets the signaling lymphocytic activation molecule family 7 (SLAMF7) expressed on the surface of MM and NK cells. …”
Get full text

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy by Amelia C. McCue, Stephen J. Demarest, Karen J. Froning, Michael J. Hickey, Stephen Antonysamy, Brian Kuhlman

“…This study showcases an approach to developing immune-modulating therapeutics that prioritizes safety and has the potential to advance cancer immunotherapy treatment strategies.…”
Get full text

Reprogramming of Melanoma Tumor-Infiltrating Lymphocytes to Induced Pluripotent Stem Cells by Hidehito Saito, Keisuke Okita, Noemi Fusaki, Michael S. Sabel, Alfred E. Chang, Fumito Ito

“…The ability to reprogram TILs containing patient-specific tumor-reactive repertoire might allow the generation of patient- and tumor-specific polyclonal T cells for cancer immunotherapy.…”
Get full text